Morgan Lee Lekstrom Acquires 147,000 Shares of Biosig Technologies (NASDAQ:STEX) Stock

Biosig Technologies, Inc. (NASDAQ:STEX) Chairman Morgan Lee Lekstrom acquired 147,000 shares of the business’s stock in a transaction dated Thursday, May 21st. The stock was acquired at an average cost of $1.04 per share, with a total value of $152,880.00. Following the completion of the transaction, the chairman owned 269,500 shares of the company’s stock, valued at approximately $280,280. The trade was a 120.00% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.

Morgan Lee Lekstrom also recently made the following trade(s):

• On Tuesday, April 14th, Morgan Lee Lekstrom sold 12,759 shares of Biosig Technologies stock. The shares were sold at an average price of $1.07, for a total value of $13,652.13.

Biosig Technologies Trading Up 3.7%

Shares of STEX traded up $0.04 during mid-day trading on Thursday, reaching $1.13. The company’s stock had a trading volume of 1,930,935 shares, compared to its average volume of 1,860,051. Biosig Technologies, Inc. has a 1-year low of $0.70 and a 1-year high of $14.11. The stock has a market cap of $204.69 million, a PE ratio of -0.12 and a beta of 1.58. The business’s 50-day moving average price is $1.21.

Biosig Technologies (NASDAQ:STEX) last announced its earnings results on Thursday, May 14th. The company reported $999.00 earnings per share for the quarter.

Analyst Ratings Changes

STEX has been the topic of a number of recent research reports. Weiss Ratings upgraded Biosig Technologies from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, May 1st. Wall Street Zen lowered Biosig Technologies from a “hold” rating to a “strong sell” rating in a research note on Sunday, April 5th. Finally, Needham & Company LLC lowered their target price on Biosig Technologies from $9.00 to $8.00 and set a “buy” rating on the stock in a research note on Thursday. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $8.00.

About Biosig Technologies

Biosig Technologies (NASDAQ:STEX) is a medical technology company focused on developing advanced signal acquisition and processing solutions for cardiac electrophysiology. The company’s work centers on improving the clarity and interpretability of intracardiac signals captured during electrophysiology procedures, with the goal of helping clinicians identify arrhythmogenic substrates and make more informed procedural decisions.

Its primary offering is a signal-processing platform that combines proprietary hardware and software to amplify, filter and display intracardiac electrical activity with reduced noise and distortion.